TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37527887

Group type: EXPERIMENTAL
Intervention: Mobile health app for self-reporting
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mobile health app usability
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Descriptive and multivariate statistics
Number of subjects: 200
Study: 37527890

Group type: EXPERIMENTAL
Intervention: Peer-supported, WhatsApp-assisted lifestyle modification intervention delivered by a trained nutritionist for 1 year (3 days after baseline and then monthly).
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Peer-supported, WhatsApp-assisted lifestyle modification intervention.
Number of subjects: 50
Study: 37527898

Group type: EXPERIMENTAL
Intervention: Bedtime use of antihypertensives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morning use of antihypertensives
Number of subjects: 0
Study: 37527897

Group type: EXPERIMENTAL
Intervention: Clinician-delivered education followed by 12 months of motivational interviewing (MI)-based health coaching
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 350
Study: 37527906

Group type: EXPERIMENTAL
Intervention: CD30-directed CAR-T cells
Number of subjects: 28
Study: 37528149

Group type: EXPERIMENTAL
Intervention: Uncommon, putatively functional genetic variants in TRD cases
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Pre-selected gene sets related to lithium response
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Previous TRD studies genes
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: ZNF248 and STK19
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: PHYIN1 and PRKRA
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: SLC7A8
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: ZDHHC3
Number of subjects: 149
Study: 37528259

Group type: EXPERIMENTAL
Intervention: Social jetlag (SJL) group
Number of subjects: 1002

Group type: COMPARATOR
Intervention: No social jetlag (no-SJL) group
Number of subjects: 1002
Study: 37528295

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET) parameters Z-scores
Number of subjects: 909
Study: 37528337

Group type: EXPERIMENTAL
Intervention: Migraine with aura
Number of subjects: 1589

Group type: COMPARATOR
Intervention: All other headaches
Number of subjects: 1589

Group type: COMPARATOR
Intervention: No headaches
Number of subjects: 1589
Study: 37528343

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (unrelated individuals)
Number of subjects: 0
Study: 37528391

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 803

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 803
Study: 37528405

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) therapy including non-vitamin K antagonist oral anticoagulants (NOACs)
Number of subjects: 2929

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 2929
Study: 37528410

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) exposure therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Progressive muscle relaxation training (Control)
Number of subjects: 46
Study: 37528500

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg (rescue treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upadacitinib (7.5 mg, 15 mg, 30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37528520

Group type: EXPERIMENTAL
Intervention: New treatments for lupus nephritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost of therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistant disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific therapies
Number of subjects: 0
Study: 37528526

Group type: EXPERIMENTAL
Intervention: A2-CAR T cells (3 million)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A2-CAR T cells (<3 million) with PBMCs
Number of subjects: 0
Study: 37528544

Group type: EXPERIMENTAL
Intervention: Health psychological group intervention
Number of subjects: 10
Study: 37528797

Group type: EXPERIMENTAL
Intervention: Plasma proteomic profiling at T1, T2, and T3
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Higher levels of TXNDC5, CTSL, and NPC2 at T2
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Machine learning-based prediction model incorporating TXNDC5, CTSL, NPC2, CPB time, and massive blood transfusion
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Model performance after 10-fold cross-validation
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: External validation of the model
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: TXNDC5 and CTSL protein levels in lung tissue of LIRI rats
Number of subjects: 709
Study: 37529001

Group type: EXPERIMENTAL
Intervention: 2'-fucosyllactose (2'-FL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2'-fucosyllactose (2'-FL) with/without resistant starch (RS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2'-fucosyllactose (2'-FL) with resistant starch (RS)
Number of subjects: 10
Study: 37529054

Group type: EXPERIMENTAL
Intervention: Values exercise based on the Disconnected Values Model (DVM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants without a disconnect
Number of subjects: 0
Study: 37529157

Group type: EXPERIMENTAL
Intervention: SHR-1802 (anti-LAG-3 monoclonal antibody) administered once every 21-day cycle, with doses escalating from 0.3 to 10 mg/kg
Number of subjects: 28
Study: 37529158

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 23
Study: 37529266

Group type: EXPERIMENTAL
Intervention: Fetal exposed (born 1959-1961)
Number of subjects: 3418

Group type: EXPERIMENTAL
Intervention: Child exposed (born 1949-1958)
Number of subjects: 3418

Group type: EXPERIMENTAL
Intervention: Adolescent/adult exposed (born 1931-1948)
Number of subjects: 3418

Group type: COMPARATOR
Intervention: Unexposed (born 1962-1978)
Number of subjects: 3418
Study: 37529919

Group type: EXPERIMENTAL
Intervention: Palbociclib with aromatase inhibitors
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Palbociclib with fulvestrant
Number of subjects: 100
Study: 37530453

Group type: EXPERIMENTAL
Intervention: Plasma aldosterone levels measured 2-4 days after MI
Number of subjects: 119
Study: 37530456

Group type: EXPERIMENTAL
Intervention: Naltrexone (light drinkers)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nalmefene (heavy drinkers)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 37530622

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity (Cohort A, B, C)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity (Cohort C)
Number of subjects: 243
Study: 37530627

Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610) with ruxolitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: JAKi monotherapy (ruxolitinib, fedratinib, momelotinib)
Number of subjects: 0
Study: 37530631

Group type: EXPERIMENTAL
Intervention: Nanatinostat 20 mg daily, 4 days per week with valganciclovir 900 mg orally daily for 28-day cycles (phase 2)
Number of subjects: 55
Study: 37530660

Group type: EXPERIMENTAL
Intervention: Transperitoneal robotic partial nephrectomy (TRPN)
Number of subjects: 2879

Group type: EXPERIMENTAL
Intervention: Retroperitoneal robotic partial nephrectomy (RRPN)
Number of subjects: 2879
Study: 37530662

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy (CN)
Number of subjects: 651

Group type: COMPARATOR
Intervention: No cytoreductive nephrectomy (no CN)
Number of subjects: 651
Study: 37530697

Group type: EXPERIMENTAL
Intervention: Post-transplantation cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37530822

Group type: EXPERIMENTAL
Intervention: High-dose VX-548
Number of subjects: 577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: VX-548 (high-dose)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: VX-548
Number of subjects: 577
Study: 37530824

Group type: EXPERIMENTAL
Intervention: Escitalopram or bupropion XL for 52 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 150
Study: 37530855

Group type: EXPERIMENTAL
Intervention: Anterior implant treatment
Number of subjects: 39
Study: 37530892

Group type: EXPERIMENTAL
Intervention: Two flap palatoplasty (TFP)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Furlow palatoplasty with buccal myomucosal flap (FPBF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (non-cleft subjects)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison between TFP and control group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison between FPBF and control group
Number of subjects: 28
Study: 37530953

Group type: EXPERIMENTAL
Intervention: Light-adapted (LA) 3 ERG
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Photopic negative response (PhNR)
Number of subjects: 214
Study: 37531031

Group type: EXPERIMENTAL
Intervention: EyeSi surgical simulator training for first-year ORs
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EyeSi surgical simulator
Number of subjects: 41
Study: 37531083

Group type: EXPERIMENTAL
Intervention: LY3405105 monotherapy (20 mg QD)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: LY3405105 monotherapy (1-2 mg orally, escalated)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: LY3405105 monotherapy (QD vs TIW dosing)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: LY3405105 monotherapy (≥15 mg QD)
Number of subjects: 54
Study: 37531093

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir-ritonavir
Number of subjects: 85
Study: 37531100

Group type: EXPERIMENTAL
Intervention: Long-term intervention (LTI) - 4 years, 412 adolescents
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Short-term intervention (STI) - 2 years, 504 adolescents
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Control - standard curriculum, 441 adolescents
Number of subjects: 1326
Study: 37531115

Group type: EXPERIMENTAL
Intervention: 5.9% THC cannabis
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: 13.4% THC cannabis
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo (0.02% THC)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Driving simulator performance
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: FST components
Number of subjects: 184

Group type: COMPARATOR
Intervention: FST performance
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Officer estimation
Number of subjects: 184
Study: 37531130

Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe (rosuvastatin, 10 mg with ezetimibe, 10 mg)
Number of subjects: 3780
Study: 37531633

Group type: EXPERIMENTAL
Intervention: Gradient boosting full model (GBf)
Number of subjects: 4075

Group type: EXPERIMENTAL
Intervention: Logistic regression model (LR)
Number of subjects: 4075

Group type: COMPARATOR
Intervention: Single undetectable hs-cTnT-based strategy (u-cTn)
Number of subjects: 4075

Group type: EXPERIMENTAL
Intervention: Machine-learning models and LR
Number of subjects: 4075
Study: 37531657

Group type: EXPERIMENTAL
Intervention: Dose 4 of vaccine at previously received antigen levels (100 or 200 μg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 37531701

Group type: EXPERIMENTAL
Intervention: Telemedicine ICU Recovery Clinic assessments
Number of subjects: 17
Study: 37531986

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25% bupivacaine
Number of subjects: 180

Group type: COMPARATOR
Intervention: 20 mL of normal saline
Number of subjects: 180

Group type: COMPARATOR
Intervention: No administration
Number of subjects: 180
Study: 37532066

Group type: COMPARATOR
Intervention: Diet-induced weight loss and standard care
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Three exercise sessions per week in adjunct to diet-induced weight loss
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Six exercise sessions per week in adjunct to diet-induced weight loss
Number of subjects: 80
Study: 37532157

Group type: EXPERIMENTAL
Intervention: Parenteral treprostinil
Number of subjects: 29
Study: 37532250

Group type: EXPERIMENTAL
Intervention: Dexamethasone intracanalicular insert
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prednisolone eyedrops (tapering schedule)
Number of subjects: 20
Study: 37532416

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin-AVD
Number of subjects: 41
Study: 37532482

Group type: EXPERIMENTAL
Intervention: Conventional radiofrequency treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 200
Study: 37532611

Group type: EXPERIMENTAL
Intervention: Tetravalent live attenuated dengue vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 37532622

Group type: EXPERIMENTAL
Intervention: SYN120 (100 mg/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 37532921

Group type: COMPARATOR
Intervention: Moderate physical activity
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: High glucose high fat dietary patterns
Number of subjects: 240

Group type: COMPARATOR
Intervention: Monomethyl phthalate (MMP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Monobutyl phthalate (MnBP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Consumption of vegetables, fruits, and tonic
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Consumption of fried food, western fast food, carbonated drinks, and juice
Number of subjects: 240
Study: 37532929

Group type: EXPERIMENTAL
Intervention: Pharmacological targeting of netrin-1
Number of subjects: 0
Study: 37532933

Group type: EXPERIMENTAL
Intervention: Next-generation probiotics, specific details on dosage and duration not available
Number of subjects: 0
Study: 37532979

Group type: EXPERIMENTAL
Intervention: Active tVNS stimulation (stimulation at cymba conchae of left ear)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tVNS stimulation (at earlobe)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active tVNS stimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tVNS stimulation
Number of subjects: 40
Study: 37532985

Group type: EXPERIMENTAL
Intervention: Higher doses of antipsychotics
Number of subjects: 0
Study: 37533033

Group type: EXPERIMENTAL
Intervention: L-carnitine (1 g of LC-L-tartrate and 3 g of leucine per day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (4 g of leucine per day)
Number of subjects: 27
Study: 37533058

Group type: EXPERIMENTAL
Intervention: tDCS treatment (active)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham tDCS treatment (placebo)
Number of subjects: 80
Study: 37533073

Group type: EXPERIMENTAL
Intervention: Patient-centered multifactorial fall injury prevention intervention
Number of subjects: 5451

Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 5451
Study: 37533096

Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) for 12 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 72
Study: 37533228

Group type: EXPERIMENTAL
Intervention: Long-term temozolomide (TMZ) treatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 6
Study: 37533380

Group type: EXPERIMENTAL
Intervention: Trazpiroben 5 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Trazpiroben 25 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Trazpiroben 50 mg
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Trazpiroben (all doses combined)
Number of subjects: 242
Study: 37533416

Group type: EXPERIMENTAL
Intervention: Usual care plus evening mobilisation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study: 37533418

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 2939

Group type: EXPERIMENTAL
Intervention: Awareness of antibody response
Number of subjects: 2939

Group type: EXPERIMENTAL
Intervention: Higher adherence
Number of subjects: 2939
Study: 37533419

Group type: EXPERIMENTAL
Intervention: MV(D614) booster
Number of subjects: 3077

Group type: EXPERIMENTAL
Intervention: MV(B.1.351) booster
Number of subjects: 3077

Group type: EXPERIMENTAL
Intervention: BiV booster
Number of subjects: 3077

Group type: EXPERIMENTAL
Intervention: All booster formulations
Number of subjects: 3077

Group type: EXPERIMENTAL
Intervention: All booster groups
Number of subjects: 3077
Study: 37533476

Group type: EXPERIMENTAL
Intervention: High Intracranial Calcification Score (ICCS)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Low Intracranial Calcification Score (ICCS)
Number of subjects: 531
Study: 37533523

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite toothpaste (test)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Fluoride toothpaste (1450 ppm fluoride; positive control)
Number of subjects: 189
Study: 37533588

Group type: EXPERIMENTAL
Intervention: Ketamine treatment (serial intravenous infusions)
Number of subjects: 26
Study: 37533657

Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy (HILT) + stretching exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT) + stretching exercise
Number of subjects: 40
Study: 37533665

Group type: EXPERIMENTAL
Intervention: Single high-intensity interval training session
Number of subjects: 0
Study: 37533773

Group type: EXPERIMENTAL
Intervention: Benralizumab (add-on treatment)
Number of subjects: 0
Study: 37533867

Group type: EXPERIMENTAL
Intervention: rBCG-N-hRSV vaccine
Number of subjects: 0
Study: 37533941

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37533995

Group type: EXPERIMENTAL
Intervention: Active stimulation group (rTMS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 60
Study: 37534453

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 37534515

Group type: EXPERIMENTAL
Intervention: Duplex Sequencing (DS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Multiparametric Flow Cytometry (MFC)
Number of subjects: 62
Study: 37534514

Group type: EXPERIMENTAL
Intervention: Minor clone of del(17p) at relapse
Number of subjects: 995

Group type: COMPARATOR
Intervention: Patients without del(17p) during follow-up
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Patients who acquired del(17p) during their disease course
Number of subjects: 995
Study: 37534543

Group type: EXPERIMENTAL
Intervention: Fostamatinib (a SYK inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 37534686

Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proactive management of adverse events
Number of subjects: 0
Study: 37534695

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination in PWH
Number of subjects: 512

Group type: COMPARATOR
Intervention: COVID-19 vaccination in HIV-negative individuals
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination in PWH with past COVID-19 infection
Number of subjects: 512

Group type: COMPARATOR
Intervention: COVID-19 vaccination in HIV-negative individuals with past COVID-19 infection
Number of subjects: 512
Study: 37534922

Group type: EXPERIMENTAL
Intervention: Upper-body ergometer rowing exercise
Number of subjects: 0
Study: 37534999

Group type: EXPERIMENTAL
Intervention: Nanovesicle technology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy using nanovesicles
Number of subjects: 0
Study: 37534996

Group type: EXPERIMENTAL
Intervention: gemcitabine plus nab-paclitaxel in combination with indoximod
Number of subjects: 16
Study: 37535240

Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (AVAL) at a dosage of 20 mg/kg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (AVAL) at a dosage of 40 mg/kg
Number of subjects: 91
Study: 37535316

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen during exercise training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Medical air during exercise training
Number of subjects: 28
Study: 37535330

Group type: EXPERIMENTAL
Intervention: Online circuit training (3 sessions per week for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (website to help reach physical activity guidelines)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Online circuit training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 37535352

Group type: EXPERIMENTAL
Intervention: PediAppRREST app
Number of subjects: 300

Group type: COMPARATOR
Intervention: PALS control group (paper-based cognitive aid)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Null control group (no cognitive aids)
Number of subjects: 300
Study: 37535357

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive behavioral therapy (tele-CBT) consisting of 6 weekly 1-hour sessions and a booster session 1 month later.
Number of subjects: 306

Group type: COMPARATOR
Intervention: Standard postoperative bariatric care (control group).
Number of subjects: 306
Study: 37535377

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy (200 mg camrelizumab, nab-paclitaxel 130 mg/m2, cisplatin 75 mg/m2 or carboplatin AUC 5 or nedaplatin 100 mg/m2)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 94
Study: 37535382

Group type: EXPERIMENTAL
Intervention: Aflibercept, 8 mg (70 μL)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Aflibercept, 2 mg (50 μL)
Number of subjects: 106
Study: 37535388

Group type: EXPERIMENTAL
Intervention: Avelumab every 2 weeks until progression, unacceptable toxic effects, or patient refusal
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard second-line chemotherapy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 122
Study: 37535416

Group type: EXPERIMENTAL
Intervention: Machine Learning Clinical Decision Support (ML-CDS) tool
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: ML-CDS intervention
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: ML-CDS tool
Number of subjects: 339